Showing 1 - 8 of 8 Urinary Tract, Sexual Organs, and Pregnancy Conditions
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spr ... Read more >

Ad5-SGE-REIC in prostate cancer

Status: Enrolling

Investigator: Brian Miles

Study Coordinator: Vivian MacDonnell

Phone: 714.441.8113

This is a phase 1/2a clinical trial in subjects who are diagnosed with prostate cancer to evaluate the effectiveness of Ad5-SGE-REIC/Dkk-3 in the treatment of localized prostate cancer. Subjects enrolled will be diagnosed with localized prostat ... Read more >

Astellas 0113-CL-2001 CMV Vaccine

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Adam Daniels

Phone: 713.441.6232

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >

Belatacept Kidney Transplant Conversion Study

Status: Enrolling

Investigator: Richard Knight

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >

GOG 0724

Status: Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This randomized phase III trial is studying chemotherapy and pelvic radiation therapy to see how well they work when given with or without additional chemotherapy in treating patients with high-risk early-stage cervical cancer after radical hyst ... Read more >

IMagyn050

Status: Open Not Enrolling

Investigator: Aparna Kamat

Study Coordinator: Jaya Kamath

Phone: 713.441.6616

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants wi ... Read more >

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Enrolling

Investigator: Kirk Heyne

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced uro ... Read more >

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)

Status: Enrolling

Investigator: Jorge Darcourt

Study Coordinator: Syed Muhammad Saad

Phone: 281.276.5263

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have re ... Read more >

Live Chat Available